A series of debates to take psoriasis management forward

17.00–19.00
Tuesday 9 June 2015
East Ballroom ABC
Vancouver Convention Center

Vancouver, Canada

Program

17.00-17.05 Welcome and introduction

Richard Langley

Dalhousie University, Halifax, Nova Scotia,

Canada

17.05-17.35 Debate 1: Is PASI 90 the new PASI 75?

Diamant Thaçi

Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck,

Germany

Robert Bissonnette

Innovaderm Research Inc., Montreal, Québec,

Canada

17.35-18.05 Debate 2: Anti-TNFs as the gold standard

for treating psoriatic arthritis: for how much

longer?

Richard Warren

University of Manchester, Manchester, UK

Wolf-Henning Boehncke

University of Geneva, Geneva, Switzerland

Supported by



Novartis Pharma AG CH-4056 Basel, Switzerland 18.05–18.35 Debate 3: Is it time for biologics as first-line treatment in psoriasis?

Diamant Thaçi

Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck,

Germany

Richard Warren

University of Manchester, Manchester, UK

18.35-18.55 Question and answer session

Moderator: Richard Langley

Dalhousie University, Halifax, Nova Scotia,

18.55-19.00 Meeting close

Richard Langley

Dalhousie University, Halifax, Nova Scotia,

Canada

IL-17A

Invitation is extended to Healthcare Professionals only

April 2015/GMCC code GLDEIM/AIN457A/0062a/Expiry April 2016 Copyright © 2015 Novartis Pharma AG

